Home Contact Sitemap
About Us Publications Work In Progress Education and Events Privacy Information for Scientists  


Aboriginal People (10)
Asthma (49)
Cancer (184)
Cardiovascular (444)
Continuity of Care (28)
Decision-Making (53)
Diabetes (146)
Diagnostic Testing (74)
Drugs (394)
Emergency Services (122)
Ethics (10)
Geriatrics (173)
Health Economics (73)
Health Human Resources (54)
Health Policy (135)
Health Technology Assessment (22)
Home Care (20)
Mental Health (85)
Methods (155)
Miscellaneous/Other (20)
Musculoskeletal (78)
Nephrology (37)
Neurology (40)
Outcomes (257)
Pediatrics (130)
Performance Measurement (49)
Population Health (117)
Primary Care (156)
Privacy (6)
Resource Utilization (109)
Respiratory (61)
Screening (59)
Stroke (84)
Surgery (113)
Urology (12)
Vascular (17)
Waiting Lists (44)
Women's Health (135)
 
  View publications
  |




Levothyroxine dose and risk of fractures in older adults: Nested case-control study

Turner MR, Camacho X, Fischer HD, Austin PC, Anderson GM, Rochon PA, Lipscombe LL. Levothyroxine dose and risk of fractures in older adults: Nested case-control study. BMJ.  2011; 342: d2238.

Objective — To quantify the effect of levothyroxine dose on risk of fractures in older adults.

 

Design — Nested case-control study.

 

Setting — Population based health databases, Ontario, Canada.

 

Participants — Adults aged 70 or more prescribed levothyroxine between 1 April 2002 and 31 March 2007 and followed for fractures until 31 March 2008. Cases were cohort members admitted to hospital for any fracture, matched with up to five controls from within the cohort who had not yet had a fracture.

 

Main Outcome Measure — Primary outcome was fracture (wrist or forearm, shoulder or upper arm, thoracic spine, lumbar spine and pelvis, hip or femur, or lower leg or ankle) in relation to levothyroxine use (current, recent past, remote). Risk among current users was compared between those prescribed high, medium, and low cumulative levothyroxine doses in the year before fracture.

 

Results — Of 213,511 prevalent levothyroxine users identified, 22,236 (10.4%) experienced a fracture over a mean 3.8 years of follow-up, 18,108 (88%) of whom were women. Compared with remote levothyroxine use, current use was associated with a significantly higher risk of fracture (adjusted odds ratio 1.88, 95% confidence interval 1.71 to 2.05), despite adjustment for numerous risk factors. Among current users, high and medium cumulative doses (>0.093 mg/day and 0.044–0.093 mg/day) were associated with a significantly increased risk of fracture compared with low cumulative doses (<0.044 mg/day): 3.45 (3.27 to 3.65) and 2.62 (2.50 to 2.76), respectively.

 

Conclusion — Among adults aged 70 or more, current levothyroxine treatment was associated with a significantly increased risk of fracture, with a strong dose-response relation. Ongoing monitoring of levothyroxine dose is important to avoid overtreatment in this population.


About Us Publications Work In Progress Education and Events Privacy Information for Scientists  

Copyright© 1992-2011 Institute for Clinical Evaluative Sciences (ICES)

Terms of Use
ICES logo - Institute for Clinical Evaluative Sciences (ICES) Home Page ICES Home Page Link Sitemap: Can't find what you are looking for? Click here for a list of webpages available to you.